The U.S. Food and Drug Administration (FDA) has pulled a television commercial promoting the use of the migraine medication Imitrex. According to FDA officials, the advertisement portrays the drug as being superior to all other pain reliever medications, but because no studies currently exist comparing Imitrex to other prescription pain relievers, the statements are unsubstantiated. GlaxoSmithKline, the drug's maker, agreed to discontinue the commercial as well as other advertisements about sumatriptan succinate side effects that make similar claims.